The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
£8 was mentioned more than ample times so probably convinced myself that that is achievable. Mind you, much harder to increase life span of patients with poor prognosis in comparison to placing £6.5B on the table. Let’s meet Hasiba’s forecast of 24p before XMass and then pending modi1 results, the sky will be the limit.
It looks the SP is on hold pending modi1 update. LD&Co seems to be very confident on progress outcome and body language / lovely results so far suggests next update will ignite the imagination of big boys of what is possible.
Good summary of what is happening. Vacuum between RNSs and weakening of SP. Unfortunately regardless of the enormous scientific advances and that will continue up to a TO or commercialisation of platforms/products. Too big tasks on the shoulders of 40 employees.
It is puzzling why SC and the ongoing trail are not mentioned. Instead the article is with references to a study base on 16 patients with tailor made treatment. Wishing them all the best and hope it works.
Always thought that success can be diluted over time. It’s great that you have not lost the believe in SC & LD.
Modi1 feedback so far and cash investment in new tech for modi2 are both indications to modi1 trail success outcome. Very interesting period.GLA
The revolutionary idea of ??the Israeli start-up company
Imagene, an Israeli start-up company, came up with a revolutionary idea: each unique mutation will have its own effect on the cancer cell. Therefore cancer cells carrying different mutations will look different. The problem - the human eye is not able to find the differences, they are too small. To overcome the problem, the company uses the digital pathology capability of the Institute of Pathology in Ichilov. Thanks to this ability, the appearance of the tumor under the microscope can be turned into extremely high resolution images. The company has developed a special algorithm, capable of identifying the unique appearance of cells that have different mutations. In this way, the presence of a mutation can be predicted within minutes, immediately after looking at the tumor under a microscope, without the need for a complex genetic test